UBS O'Connor’s Acadia Pharmaceuticals ACAD Stock Holding History

UBS O'Connor’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-10,000	Closed	-$7K	–	433
2013 Q4	$7K	Buy	+10,000	New	+$236K	﹤0.01%	392

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

UBS O'Connor's ACAD Position: Q3 2025 in Review

UBS O'Connor sold out of Acadia Pharmaceuticals (ACAD) in Q3 2025, closing a stake of 43,000 shares — an estimated $928K sold.

UBS O'Connor first reported a position in ACAD in Q1 2014 and held it in 3 quarters. The position peaked at $928K in Q2 2025. 334 funds tracked by Wall St. Rank hold ACAD as of Q3 2025.

UBS O'Connor reported no remaining Acadia Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
UBS O'Connor sold 43,000 Acadia Pharmaceuticals shares in Q3 2025, an estimated $928K.
UBS O'Connor first reported a position in Acadia Pharmaceuticals in Q1 2014 and held it in 3 quarters.
UBS O'Connor's Acadia Pharmaceuticals position peaked at $928K in Q2 2025.
334 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.